NCT04509102Enrolling by invitationEarly phase 1
Psychostimulant Augmentation of Repetitive TMS for the Treatment of Major Depressive Disorder
*Full Title of the Submission: Psychostimulant Augmentation of Repetitive TMS (rTMS) for the Treatment of Major Depressive Disorder: A Randomized, Placebo-controlled Clinical Trial
Source: ClinicalTrials.gov · Last updated 3 Feb 2026
Brief summary (registry, in English)
This study analyzes the affects or Adderall extended-release (XR) in Subjects receiving brain stimulation therapy for the treatment of Major Depressive Disorder. Subjects will be assigned by chance to active or placebo group. Active group will be asked to take one 15 mg pill once daily of Adderall XR (amphetamine) and the Placebo group will be asked take an identical appearing tablet/capsule, one tablet by mouth daily. The placebo tablet has no active ingredients and has no affect on the body or mind. With the exception of the study drug, all other study activities between both groups will be identical. Subjects will use the assigned study drug two weeks before therapy and throughout the first 10 therapy treatments. A total of seven(7) visits will be required for screening, drug assignment, and completion of mood assessments. This study will enroll a total of 30 Subjects.
- Status (registry)
- Enrolling by invitation
- Phase (registry)
- Early phase 1
- Study type
- Interventional
- Enrollment
- 30 (estimated)
- First submitted
- 29 Jun 2020
- Start date
- 27 Sept 2021
- Primary completion date
- 1 Dec 2027
- Lead sponsor
- University of California, Los Angeles
- Diseases
- Depression
- NCT number
- NCT04509102
What you commit to
- Study type: Interventional · Early phase 1
- Planned participants: 30
- From 27 Sept 2021 to the primary completion date, 1 Dec 2027
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Current use of psychostimulant medication
- Current use of an Monoamine oxidase inhibitors (MAOI) or use of an MAOI within the past two weeks
Other illness
- Lifetime diagnosis of bipolar affective disorder
- Lifetime diagnosis of major depressive disorder with psychotic features, schizophrenia, schizoaffective disorder, or any other psychotic disorder
- History of psychotic symptoms
- Lifetime diagnosis of substance use disorder
- History of stimulant misuse or abuse
- History of hypersensitivity to Adderall XR
- History of intolerance of any psychostimulant medication
- Presence of motor tics or family history of tic disorder
- Symptomatic cardiovascular disease including hypertension, coronary artery disease, arteriosclerosis, cardiomyopathy, or arrhythmia
- Structural cardiac abnormalities
- Family history of sudden cardiac death in a first degree relative
- History of epilepsy or seizure
- History of stroke
- History of brain tumor
Other
- Inability to give informed consent
- Active substance abuse
- Anxiety, tension, or agitation that is of sufficient severity to make it difficult for the subjects to tolerate psychostimulants and/or 10 Hz rTMS treatment
- Current use of benzodiazepines
- Pregnancy, breastfeeding, or plans to become pregnant during the study period
- Glaucoma
- Hyperthyroidism
- Presence of any metal in the head
- Presence of pacemaker or medical devices implanted close to the site of magnetic stimulation
Who the study is looking for
- All subjects will be between the ages of 18-65 and will meet DSM-V criteria for a current episode of major depressive disorder.
- Meet criteria for treatment resistance as defined by lack of response to two prior antidepressant trials at adequate dosage and duration. Participants may use any psychotropic medications other than psychostimulants or benzodiazepines, and may continue these medications during the study.
- The outside treating psychiatrist must agree that enrollment in the study is safe and acceptable for the subject.
Age in the registry: 18 years to 65 years · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| UCLA Semel Coordinator of this site? Confirm its status | Los Angeles | United States | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.